Joel R. Hardink
Pfizer (United States)(US)
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Protease and Inhibitor Mechanisms, Antibiotics Pharmacokinetics and Efficacy, Peptidase Inhibition and Analysis, Bacterial Genetics and Biotechnology
Most-Cited Works
- → Preparation, Gram-Negative Antibacterial Activity, and Hydrolytic Stability of Novel Siderophore-Conjugated Monocarbam Diols(2011)70 cited
- → Pyridone-Conjugated Monobactam Antibiotics with Gram-Negative Activity(2013)63 cited
- → Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14(2005)59 cited
- → Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV(2013)56 cited
- → Discovery of Dap-3 Polymyxin Analogues for the Treatment of Multidrug-Resistant Gram-Negative Nosocomial Infections(2013)55 cited
- → Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections(2009)54 cited
- → Potent, selective pyrimidinetrione-based inhibitors of MMP-13(2006)47 cited
- → Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13(2005)44 cited
- → In VivoandIn VitroAntimalarial Properties of Azithromycin-Chloroquine Combinations That Include the Resistance Reversal Agent Amlodipine(2011)43 cited
- → Synthesis and biological activity of piperazine-Based dual MMP-13 and TNF-α converting enzyme inhibitors(2003)40 cited